Bahr undertook a complete re-examination of the tome, complete with spectroscopic analysis and mathematical investigation, to ...

In addition, Knight may pay future contingent payments of up to US$15 million upon achieving certain sales milestones. In 2024, Paladin generated revenues of $70 million excluding products that ...

Montreal-based Knight Therapeutics has galloped in with CAD $120 million ($84 million) to pick up Endo’s Paladin Pharma unit in a move that stands to significantly expand its Canadian business.

In addition, Knight may pay future contingent payments of up to US$15 million upon achieving certain sales milestones. In 2024, Paladin generated revenues of $70 million excluding products that ...

Knight Therapeutics Inc. GUD-T has signed a deal to buy the assets of Paladin Pharma Inc. as the Canadian drug company looks to build out its domestic business after a strategic push into South ...

Davies Ward Phillips & Vineberg LLP; Paladin Pharma Inc. Knight Therapeutics Inc. has entered into a definitive Asset Purchase Agreement (“APA”) with Endo Operations Limited (“Endo”) and Paladin ...

In a move set to reshape the Canadian pharmaceutical landscape, Knight Therapeutics Inc. has agreed to acquire Paladin Pharma from Endo Inc. for up to $99 million. The transaction, announced Tuesday, ...